Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant for Insomnia in Opioid Use Disorder Patients on Buprenorphine
NCT06981195Phase 2Recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- May 2025
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Insomnia comparing Placebo with Lemborexant 10 MG (2 arms). Primary endpoints: Insomnia Severity at 8 weeks and Impulsivity at 8 weeks. Started May 2025; status: recruiting.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06981195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981195.